Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 3 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $2.51B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $441.1K in total
- 3
- 13F holdersQ2 2026, +26 vs. previous quarter
- 239
- 13F valueReported value at the end of Q2 2026
- $2.51B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NKTR, Q2 2026
No superinvestor reported holding NKTR at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nektar Therapeutics insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)7:05 PM ET | Aug 18 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −186 | $71.98 | −$13.4K | −1.9%9.57K after | |
| Aug 20, 2026 (view filing)7:03 PM ET | Aug 18 | 2 days | Robin Howard WPresident & CEO | SSale | −418 | $71.98 | −$30.1K | −0.8%54.6K after | |
| Jul 2, 2026 (view filing)7:06 PM ET | Jun 30 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −5.68K | $70.00 | −$397.7K | −36.8%9.76K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 16-17 | 2 days | Robin Howard WPresident & CEO | SSale | −20.0K | $60.75 | −$1.22M | −26.7%55.0K after | 4 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −5.54K | $60.71 | −$336.2K | −26.4%15.4K after | 10b5-1 |
| May 21, 2026 (view filing) | May 19 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −199 | $65.51 | −$13.0K | −0.9%21.0K after | |
| May 21, 2026 (view filing) | May 19 | 2 days | Robin Howard WPresident & CEO | SSale | −444 | $65.51 | −$29.1K | −0.6%75.0K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −180 | $73.00 | −$13.1K | −0.8%21.2K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Robin Howard WPresident & CEO | SSale | −423 | $73.00 | −$30.9K | −0.6%75.5K after | |
| Jan 22, 2026 (view filing) | Jan 20 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −3.87K | $35.67 | −$137.9K | −15.3%21.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nektar Therapeutics at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5,067,920 | $353.8M | 0.02% | +764,732+17.8% | Added |
| Two Seas Capital LP | 3,092,234 | $215.9M | 8.24% | +1,133,056+57.8% | Added |
| BlackRock, Inc. | 2,941,851 | $205.4M | 0.00% | +2,249,201+324.7% | Added |
| BVF Inc | 2,391,075 | $166.9M | 4.27% | −168,520−6.6% | Reduced |
| Vanguard Capital Management LLC | 1,496,849 | $104.5M | 0.00% | +299,794+25.0% | Added |
| Two Sigma Investments, LP | 1,202,004 | $83.9M | 0.06% | +271,263+29.1% | Added |
| Vestal Point Capital, LP | 1,000,000 | $69.8M | 1.63% | +715,000+250.9% | Added |
| Morgan Stanley | 936,560 | $65.4M | 0.00% | +277,173+42.0% | Added |
| State Street Corp | 909,679 | $63.5M | 0.00% | +664,952+271.7% | Added |
| Geode Capital Management, LLC | 881,306 | $61.5M | 0.00% | +534,511+154.1% | Added |